Insilico & SK Biopharm: AI Revolutionizing Drug Discovery

Insilico Medicine's lead drug, INS018_055, reached Phase II trials in 2026, marking it as the first generative AI-designed drug for an AI-discovered target to achieve this milestone. Insilico Medicine's lead drug, INS018_055, reaching Phase II trials in 2026 offers a glimpse into how artificial intelligence accelerates the search for new therapies, potentially shortening timelines for patients awaiting critical treatments. SK Biopharmaceuticals has also developed its own big data and AI-based drug design platform, alongside a genomic analysis platform, validating the broader industry trend towards AI-driven discovery.

Despite this groundbreaking progress, a significant disconnect persists in the broader life sciences industry. Over 60% of life science labs are still only exploring or piloting AI, with a mere 5% using AI agents in full production. Over 60% of life science labs still only exploring or piloting AI, with a mere 5% using AI agents in full production, creates a tension between frontier innovation and widespread practical application.

The gap between AI's proven potential in accelerating drug discovery and its practical, widespread implementation in labs is likely to widen, creating a two-tiered system in pharmaceutical innovation. The gap between AI's proven potential in accelerating drug discovery and its practical, widespread implementation in labs, likely to widen and create a two-tiered system in pharmaceutical innovation, suggests that while advanced AI platforms drive breakthroughs for some, many organizations struggle with foundational integration.

Where Labs Prioritize AI Today

Researchers prioritize AI for data analysis, workflow automation, experiment design, and sample management, according to Selectscience.

Labs prioritize AI for its immediate value in streamlining critical lab functions, particularly in data-intensive tasks. Labs prioritizing AI for its immediate value in streamlining critical lab functions, particularly in data-intensive tasks, aims to enhance efficiency and accuracy across various stages of drug discovery and development, directly impacting project timelines and resource allocation.

Generative AI Moves to Production in Key Lab Functions

A January 2026 survey of 113 life sciences professionals reveals over 60% of labs are exploring or piloting AI, with most deployments remaining experimental. A January 2026 survey of 113 life sciences professionals revealing over 60% of labs are exploring or piloting AI, with most deployments remaining experimental, highlights a significant gap between aspiration and widespread production, suggesting that initial enthusiasm often stalls at the proof-of-concept stage. Despite broad interest, only 5% of labs use AI agents in full production. Only 5% of labs using AI agents in full production, contrasted with Insilico Medicine's groundbreaking AI-designed drug reaching Phase II trials, indicates a widening chasm: a select few are leveraging AI for true innovation and accelerated discovery, while the vast majority struggle with foundational AI implementation, risking obsolescence and a permanent lag in the race for new therapies.